Plasmacytoid Dendritic Cells Alter the Antitumor Activity of CpG-Oligodeoxynucleotides in a Mouse Model of Lung Carcinoma

The effect of CpG-oligodeoxynucleotides (CpG) has been studied on a number of tumors. Although CpG may facilitate tumor regression in mouse models of melanoma, its activity in lung cancer is unclear. The aim of our study was to elucidate the effect of CpG (0.5–50 μg/mouse) in a mouse model of Lewis lung carcinoma cell-induced lung cancer. Lung tumor growth increased at 3 and 7 d after a single administration of CpG. This was associated with a greater influx of plasmacytoid dendritic cells (pDCs), immature myeloid dendritic cells, and greater recruitment of regulatory T cells. Depletion of pDCs using a specific Ab (m927) reversed the immune-suppressive environment and resulted in a decreased lung tumor burden, accompanied by a greater influx of active myeloid dendritic cells and CD8+ T cells, and a higher production of Th1- and Th17-like cytokines. Furthermore, the rate of apoptosis in the lungs of mice treated with CpG increased following the depletion of pDCs. CpG treatment alone does not lead to tumor regression in the lung. However, ablation of pDCs renders CpG a good adjuvant for lung cancer chemotherapy in this experimental model.

[1]  Shuang Chen,et al.  Plasmacytoid dendritic cells prevent cigarette smoke and Chlamydophila pneumoniae-induced Th2 inflammatory responses. , 2010, American journal of respiratory cell and molecular biology.

[2]  M. Gill,et al.  Counterregulation between the FcεRI Pathway and Antiviral Responses in Human Plasmacytoid Dendritic Cells , 2010, The Journal of Immunology.

[3]  R. Flavell,et al.  The dual nature of TH17 cells: shifting the focus to function , 2010, Nature Immunology.

[4]  R. Sorrentino,et al.  Role of plasmacytoid dendritic cells in lung-associated inflammation. , 2010, Recent Patents on Inflammation & Allergy Drug Discovery.

[5]  T. Randall,et al.  Temporal changes in dendritic cell subsets, cross-priming and costimulation via CD70 control CD8+ T cell responses to influenza , 2010, Nature Immunology.

[6]  M. Gilliet,et al.  Plasmacytoid dendritic cells: key players in the initiation and regulation of immune responses , 2010, Annals of the New York Academy of Sciences.

[7]  K. Debatin,et al.  Prostaglandin E2 Inhibits IFN-α Secretion and Th1 Costimulation by Human Plasmacytoid Dendritic Cells via E-Prostanoid 2 and E-Prostanoid 4 Receptor Engagement , 2009, The Journal of Immunology.

[8]  P. Hwu,et al.  T helper 17 cells promote cytotoxic T cell activation in tumor immunity. , 2009, Immunity.

[9]  R. Sorrentino,et al.  Cl‐IB‐MECA enhances TRAIL‐induced apoptosis via the modulation of NF‐κB signalling pathway in thyroid cancer cells , 2009, Journal of cellular physiology.

[10]  Lionel B Ivashkiv,et al.  Cross-regulation of signaling pathways by interferon-gamma: implications for immune responses and autoimmune diseases. , 2009, Immunity.

[11]  T. Miyasho,et al.  Intratracheal synthetic CpG oligodeoxynucleotide causes acute lung injury with systemic inflammatory response , 2009, Respiratory research.

[12]  Hua Yu,et al.  In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses , 2009, Nature Biotechnology.

[13]  W. Zou,et al.  Endogenous IL-17 contributes to reduced tumor growth and metastasis. , 2009, Blood.

[14]  Xin-Yuan Fu,et al.  Survivin mediates aberrant hematopoietic progenitor cell proliferation and acute leukemia in mice induced by internal tandem duplication of Flt3. , 2009, Blood.

[15]  Hua Yu,et al.  IL-17 can promote tumor growth through an IL-6–Stat3 signaling pathway , 2009, The Journal of experimental medicine.

[16]  A. Krieg,et al.  Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists. , 2009, Advanced drug delivery reviews.

[17]  Ya Zhou,et al.  TLR9 Signaling Promotes Tumor Progression of Human Lung Cancer Cell In Vivo , 2009, Pathology & Oncology Research.

[18]  Hua Yu,et al.  Toll-like receptor 9 activation of signal transducer and activator of transcription 3 constrains its agonist-based immunotherapy. , 2009, Cancer research.

[19]  G. Rallis,et al.  Prognostic Significance of p53 and Ki67 Proteins Expression in Greek Gastric Cancer Patients , 2009, Acta chirurgica Belgica.

[20]  R. Medzhitov,et al.  Toll-like receptors and cancer , 2009, Nature Reviews Cancer.

[21]  Wan-Wan Lin,et al.  Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis , 2009, Nature.

[22]  Ming Fang,et al.  Increased expression of Toll-like receptors 4 and 9 in human lung cancer , 2009, Molecular Biology Reports.

[23]  R. Schwabe,et al.  Toll-like receptors, wound healing, and carcinogenesis , 2009, Journal of Molecular Medicine.

[24]  P. Krawczyk,et al.  Phenotype of dendritic cells generated in the presence of non-small cell lung cancer antigens - preliminary report. , 2009, Folia histochemica et cytobiologica.

[25]  K. Mills.  TLR9 turns the tide on Treg cells. , 2008, Immunity.

[26]  M. Imawari,et al.  Dendritic cells stimulated with cytidine‐phosphate‐guanosine oligodeoxynucleotides and interferon‐α‐expressing tumor cells effectively reduce outgrowth of established tumors in vivo , 2008, Cancer science.

[27]  M. Kool,et al.  The Balance between Plasmacytoid DC versus Conventional DC Determines Pulmonary Immunity to Virus Infections , 2008, PloS one.

[28]  C. Liu,et al.  Plasmacytoid dendritic cells induce NK cell-dependent, tumor antigen-specific T cell cross-priming and tumor regression in mice. , 2008, The Journal of clinical investigation.

[29]  G. Weiner,et al.  CpG oligodeoxynucleotides as immunotherapy in cancer. , 2008, Update on cancer therapeutics.

[30]  E. Stockfleth,et al.  Clinical investigations of Toll-like receptor agonists. , 2008, Expert opinion on investigational drugs.

[31]  D. Schiffer,et al.  Survivin expression in glioblastomas correlates with proliferation, but not with apoptosis. , 2008, Anticancer research.

[32]  M. Kool,et al.  Dendritic cells in asthma and COPD: opportunities for drug development. , 2007, Current opinion in immunology.

[33]  D. Munn,et al.  The Indoleamine 2,3-Dioxygenase Pathway Is Essential for Human Plasmacytoid Dendritic Cell-Induced Adaptive T Regulatory Cell Generation. , 2007 .

[34]  B. Han,et al.  Low-Dose Paclitaxel Prior to Intratumoral Dendritic Cell Vaccine Modulates Intratumoral Cytokine Network and Lung Cancer Growth , 2007, Clinical Cancer Research.

[35]  B. Baban,et al.  Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. , 2007, The Journal of clinical investigation.

[36]  A. Krieg.  Development of TLR9 agonists for cancer therapy. , 2007, The Journal of clinical investigation.

[37]  X. Qin,et al.  Plasmacytoid dendritic cells prime IL-10–producing T regulatory cells by inducible costimulator ligand , 2007, The Journal of experimental medicine.

[38]  R. Schreiber,et al.  Bone Marrow Stromal Cell Antigen 2 Is a Specific Marker of Type I IFN-Producing Cells in the Naive Mouse, but a Promiscuous Cell Surface Antigen following IFN Stimulation , 2006 .

[39]  Johannes Gerdes,et al.  Human lung cancer cells express functionally active Toll-like receptor 9 , 2005, Respiratory research.

[40]  H. Hammad,et al.  Essential Role of Lung Plasmacytoid Dendritic Cells in Preventing Asthmatic Reactions to Harmless Inhaled Antigen , 2004, The Journal of experimental medicine.

[41]  K. Legge,et al.  Accelerated migration of respiratory dendritic cells to the regional lymph nodes is limited to the early phase of pulmonary infection. , 2003, Immunity.

[42]  P. Krammer,et al.  Immune escape of tumors: apoptosis resistance and tumor counterattack , 2002, Journal of leukocyte biology.

[43]  M. Stolina,et al.  T cell-derived IL-10 promotes lung cancer growth by suppressing both T cell and APC function. , 1999, Journal of immunology.